Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice
Abstract Abrocitinib is a Janus kinase (JAK) 1-selective inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD). Although specific dose recommendations for abrocitinib vary across regional product labels, abrocitinib 100 mg once daily is recommended as a starting and maint...
Main Authors: | Melinda J. Gooderham, Andrew E. Pink, Eric L. Simpson, Jonathan I. Silverberg, Erman Güler, Melissa Watkins |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2023-07-01
|
Series: | Dermatology and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s13555-023-00948-6 |
Similar Items
-
Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
by: Helena Iznardo, et al.
Published: (2023-01-01) -
Research progress on abrocitinib in the treatment of moderate and severe atopic dermatitis
by: Xu ZHU, et al.
Published: (2023-08-01) -
A Case of Perioral Dermatitis Successfully Treated with Abrocitinib
by: Teng Y, et al.
Published: (2023-10-01) -
Successful Treatment of Atopic Dermatitis with a Predominant Nipple Involvement by Abrocitinib During COVID-19 Pandemic: A Case Report
by: Teng Y, et al.
Published: (2023-08-01) -
Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry
by: Esmé Kamphuis, et al.
Published: (2024-02-01)